Search clinical trials for: JS012

Total 20 results

Shanghai Junshi Bioscience Co., Ltd.

Terminated

A Clinical Study to Evaluate the Safety and Tolerability of JS012 in Advanced or Metastatic Solid Tumors

Advanced or Metastatic Solid Tumors

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

The Efficacy and Safety of JS002 PFS and AI in Patients With Primary Hypercholesterolemia and Mixed Hyperlipidemia

Hyperlipemia

China
Shanghai Junshi Bioscience Co., Ltd.
Sponsor GmbH

Active, not recruiting

A Pharmacokinetic Study of JS002 in Healthy Subjects

Health Volunteer

China
Shanghai Junshi Bioscience Co., Ltd.
Sponsor GmbH

Recruiting

A Phase I Study Of JS015 in Patients With Advanced Solid Tumors

Advanced Solid Cancer

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

To Evaluate the Efficacy and Safety of JS002 in HoFH Patients

Hyperlipemia

China
Shanghai Junshi Bioscience Co., Ltd.

Not yet recruiting

Efficacy and Safety of JS002 as Monotherapy in Patients With Primary Hypercholesterolaemia and Mixed Dyslipidemia

Primary Hypercholesterolaemia and Mixed Dyslipidemia

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

The Safety and Efficacy of Multiple-dose of JS002 in Subject With Hyperlipidemia

Hyperlipemia

China
Sun Pharmaceutical Industries Limited

Completed

Efficacy and Safety of AS012 in Subjects With Non-segmental Vitiligo

Non-segmental Vitiligo

United States, India
Shanghai Junshi Bioscience Co., Ltd.

Completed

A Study of JS026 and JS026 Together With JS016 for Treatment of COVID-19

COVID-19

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

A Clinical Trial Evaluated the Safety and Tolerability, Pharmacokinetic and Pharmacodynamics Profile, and Immunogenicity of a Single Dose of JS010 Injection in Healthy Subjects

Migraine

China
Suzhou Kebo Ruijun Biotechnology Co., Ltd

Recruiting

A Clinical Study to Evaluate the Safety, Tolerability,JS019 in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Suzhou Kebo Ruijun Biotechnology Co., Ltd

Recruiting

A Phase 1 Study to Evaluate JS019 in Advanced Solid Tumors or Lymphomas

Advanced Solid Tumors or Lymphomas

China
Shanghai Junshi Bioscience Co., Ltd.

Terminated

A Study Explore JS001+JS002 in Patients With Advanced Cancer

Advanced Cancer

China
Peking Union Medical College Hospital

Recruiting

Efficacy and Safety of JS016 in Patients With SARS-CoV-2 Infection (COVID-19)

COVID-19 | SARS-CoV-2

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of JS002 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH).

Heterozygous Familial Hypercholesterolemia

China
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Tolerability,Safety,Pharmacokinetic Profile and Immunogenicity of a Recombinant Humanized Anti-SARS-CoV-2 Monoclonal Antibody (JS016) for Injection in Chinese Health Subjects

COVID-19; and High Infection Risk of SARS-CoV-2

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

A Single Dose Escalation Study of PCSK9 Inhibitor (JS002) in Health Subjects

Hypercholesterolemia

China
Anwita Biosciences
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Phase 1 First-in-human Study of JS014

Lymphoma | Solid Tumor, Adult | Neoplasm Malignant | Neoplasm, Experimental

Taiwan
Fudan University

Not yet recruiting

Newly Emerging Immunotherapy for Pancreatic Cancer Treatment (FD-IMPACT)

Pancreatic Cancer

China
Shanghai Junshi Bioscience Co., Ltd.
Sponsor GmbH

Not yet recruiting

A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors

Advanced Solid Tumor

China

Search clinical trials for: JS012

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Angola

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations